Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.51 |
| ▸ | AKR1C4 | P17516 | 3/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707828 | 0.91 | SMN1; SMN2 (0.53) | SMN1; SMN2AKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL1708579 | 0.81 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1LMNAGAAPOLB | |
| SCHEMBL15464127 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2AKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL1707863 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1MEN1 | |
| SCHEMBL10008943 | 0.79 | MAPK1 (0.55) | SMN1; SMN2AKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL1707815 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1LMNAGAAFFAR4 | |
| SCHEMBL10010086 | 0.78 | AKR1C3 (0.55) | SMN1; SMN2AKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL31548078 | 0.77 | SIRT6 (0.56) | SMN1; SMN2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL137523 | 0.77 | SIRT6 (0.56) | SMN1; SMN2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL307312 | 0.77 | TSHR (0.70) | SMN1; SMN2ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | SMN1; SMN2 4287/4885AKR1C3 2792/4885AKR1C2 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.